Journals / Mikrobiyoloji Bülteni / 2008 / Cilt: 42 - Sayı: 2

Suscessful treatment of a patient with multidrug resistant acınetobacter baumannıı meningitis with high dose ampicillin-sulbactam

Çoklu ilaç dirençli acinetobacter baumannıı menenjiti olgusunun yüksek doz ampisilin-sülbaktam ile başarılı tedavisi

Pages
353–358
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Since the cerebrospinal fluid (CSF) findings indicated a central nervous system infection, nosocomial meningitis was diagnosed and intravenous ceftazidime and vancomycin have started.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Acinetobacter baumannii is an important pathogen which causes severe nosocomial infections such as meningitis.
📊
Key Findings & Data:Rhinorrhea and confusion developed on the postoperative seventh day in a 67 years old male patient operated for macroadenoma of the hyphophysis gland.
💡
Conclusion & Impact:Since the cerebrospinal fluid (CSF) findings indicated a central nervous system infection, nosocomial meningitis was diagnosed and intravenous ceftazidime and vancomycin have started.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Acinetobacter baumannii is an important pathogen which causes severe nosocomial infections such as meningitis. Multidrug resistance is a growing problem throughout the world. In this report a case of multidrug resistant A.baumannii meningitis, treated with high dose of ampicillin-sulbactam (SAM) was presented. Rhinorrhea and confusion developed on the postoperative seventh day in a 67 years old male patient operated for macroadenoma of the hyphophysis gland. Since the cerebrospinal fluid (CSF) findings indicated a central nervous system infection, nosocomial meningitis was diagnosed and intravenous ceftazidime and vancomycin have started. Blood and CSF cultures of the patient revealed no growth and his general condition has improved. However, fever and confusion emerged again on the 21st day of therapy and the repeat CSF sample revealed increased pressure, purulent appearance, 510/mm3 leukocytes (90% PMNL), 58 mg/dl glucose (simultaneous blood glucose was 144 mg/dl) and 49 mg/dl protein. Direct microscopic examination of CSF revealed gram-negative coccobacilli and A.baumannii was identified in the culture. The isolate was resistant to piperacillin-tazobactam, third generation cephalosporins, aztreonam, ciprofloxacin, carbapenems and aminoglycosides, susceptible to sulbactam ampicillin and colistin. Ampicillin (12 gr) and sulbactam (6 gr) treatment was initiated and at the 72nd hour of the therapy the temperature and conciousness level of the patient returned to normal. Control CSF sample obtained on the 14th day of treatment revealed no leukocytes and no bacterial growth. The treatment was continued for 21 days and the patient recovered without any sequela. Since colistin which is one of the alternative antimicrobial treatment choices for resistant Acinetobacter infections, is not found in Turkey, sulbactam-ampicillin might be an effective and safe choice for the treatment of multi-resistant A.baumannii meningitis if the isolate was proven to be susceptible by antibiotic susceptibility tests.

Özet

Acinetobacter baumannii, menenjit gibi ciddi nozokomiyal enfeksiyonlara neden olan önemli bir patojendir. Çoklu ilaç direnci nedeniyle bu patojenin önemi tüm dünyada giderek artmaktadır. Bu raporda, çok ilaca dirençli bir A.baumannii suşuyla gelişen ve yüksek doz ampisilin-sülbaktam (SAM) ile tedavi edilen bir menenjit olgusu sunulmuştur. Hipofiz makroadenomu nedeniyle öpere edilen 67 yaşındaki bir erkek olguda, cerrahi sonrası yedinci günde rinore ve bilinç bulanıklığı gelişmiştir. BOS bulgularının merkezi sinir sistemi enfeksiyonunu işaret etmesi üzerine nozokomiyal menenjit tanısıyla hastaya ampirik olarak intravenöz seftazidim ve vankomisin tedavileri başlanmıştır. Kan ve BOS kültüründe üreme olmayan ve genel durumu düzelen olguda, tedavinin 21. gününde ateş yüksekliği (39°C) ve bilinç bozukluğu ortaya çıkmıştır. Tekrar alınan BOS örneğinin basıncı artmış, görünümü bulanık, lökosit 510/mm3(%90 PNL), glukoz 5.8 mg/dL (eş zamanlı kan glukozu 144 mg/dL) ve protein 49 mg/dL olarak saptanmıştır. BOS'nın direk incelemesinde gram-negatif kokobasiller görülmüş ve BOS kültüründe üreyen bakteri A baumannii olarak tanımlanmıştır. İzolatın piperasilin- tazobaktam, üçüncü kuşak sefalosporinler, aztreonam, siprofloksasin, karbapenemler ve aminoglikozitlere dirençli, SAM ve kolistine duyarlı olduğu saptanmıştır. Olguya 12 gr ampisilin ve 6 gr sülbaktam tedavisi başlanmış, tedavinin 72. saatinde hastanın ateşi normale dönmüş ve bilinç durumu düzelmiştir. Tedavinin 14. gününde kontrol için alınan BOS örneğinde hücre görülmemiş ve BOS kültüründe üreme olmamıştır. Tedavisi 21 güne tamamlanan olgu sekelsiz iyileşmiştir. Sonuç olarak, kolistin gibi alternatif ilaçların piyasada bulunmadığı ülkemizde SAM'ın, çok ilaca dirençli Abaumannii menenjitlerinin tedavisinde etkin ve güvenilir olarak kullanılabileceği düşünülmüştür.

🔖

Cite This Article

KUTLU, S. S., SAÇAR, S., SÜZER, T., CEVAHİR, N., ÖKKE, D., ÇAYLAK, S. D., TURGUT, H. (2008). Suscessful treatment of a patient with multidrug resistant acınetobacter baumannıı meningitis with high dose ampicillin-sulbactam. Mikrobiyoloji Bülteni, Cilt: 42 - Sayı: 2, 353–358. https://ajindex.com/articles/299005

References (12)

  1. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection: mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13: 97-103
  2. Siegman-lgra Y, Bar-Yosef S, Gorea A, Avram J. Nosocomial Acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review. Clin Infect Dis 1993; 17: 843-9
  3. Jimenez-Mejias ME, Pachon J, Becerril B, Palomino-Nicas J, Rodriguez-Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997; 24: 932-5
  4. Nicoletti G, Schito G, Fadda G, Boros S, Nicolosi D. Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting. J Chemother 2006; 18: 589-602
  5. Joshi SG„ Litake GM, Satpute MG, Telang NV, Ghole VS, Niphadkar KB. Clinical and demographic features of infection caused by Acinetobacter species. Indian J Med Sci 2006; 60: 351-60
  6. Jimenez-Mejias ME, Becerril B, Marquez-Rivas FJ, Pichardo C, Cuberos L, PaChon J. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis 2000; 12: 970-1
  7. Smolyakov R, Borer A, Riesenber K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003; 54: 32-8
  8. Ko WC, Lee HC, Chiang SR, et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 2004; 53: 393-5
  9. Wang FD, Lin ML, Lee WS, Liu CY. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against gram-negative bacteria. Int J Antimicrob Agents 2004; 23: 590-5
  10. Kuo LC, Lai CC, Liao CH, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007; 13: 196-8
  11. Panchon-lbanez MA, Jimenez-Mejias ME, Pichardo C, et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem/cilastatin. Antimicrob Agents Chemother 2004; 48: 4479-81
  12. Song JY1, Kee SY1, Hwang IS, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimi